GlassScriptPhysician profile
Gregory Mathew Wickern
NPI 1972578672
$7,884.51
in general payments reported to CMS, 2019-2025
35 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $601 · 2021: $1,048 · 2022: $1,076 · 2023: $1,532 · 2024: $1,384 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Education: $51.41 · Consulting Fee: $48.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.93 |
| Education | $51.41 |
| Consulting Fee | $48.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,514.21 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $987.38 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $940.73 | 2019-2025 | Dupixent |
| Csl Behring | $725.16 | 2019-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $704.17 | 2020-2025 | Cinryze, Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $502.52 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Blueprint Medicines Corporation | $462.60 | 2023-2025 | Ayvakit |
| Octapharma USA, INC. | $246.30 | 2020-2021 | |
| Genzyme Corporation | $215.05 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $207.33 | 2021-2023 | Proair Digihaler |
| Mylan Specialty L.P. | $174.07 | 2020-2024 | Yupelri |
| Pfizer INC. | $127.21 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $112.69 | 2020-2023 | |
| Biocryst US Sales Co., LLC | $93.99 | 2024-2025 | Orladeyo |
| Amgen INC. | $93.97 | 2023-2025 | Tezspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $77.89 | 2019-2025 | Ruconest |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Adma Biomanufacturing LLC | $71.17 | 2021-2025 | |
| Sanofi US Services INC. | $66.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.14 | 2019-2021 | |
| Genentech USA, INC. | $56.68 | 2022-2023 | Xolair |
| Ionis Pharmaceuticals, INC. | $50.70 | 2025 | Dawnzera |
| Organon LLC | $39.98 | 2025 | Vtama |
| Optinose US, INC. | $32.94 | 2019-2025 | |
| Shire North American Group INC | $32.50 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.89 | 2019 | |
| Verona Pharma, INC. | $27.16 | 2025 | Ohtuvayre |
| X4 Pharmaceuticals, INC. | $26.65 | 2024 | Xolremdi |
| Horizon Therapeutics Plc | $24.91 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.10 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $20.82 | 2025 | |
| Lilly USA, LLC | $19.46 | 2025 | Ebglyss |
| Leo Pharma INC. | $17.42 | 2025 | Anzupgo |
| Hikma Pharmaceuticals USA | $14.76 | 2023 | Ryaltris |
| Viatris Specialty LLC | $14.10 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wickern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.